NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » Company watch  «  1  2  3  4  5  » 
found files: 574
Covance »17/09/2007 [Company watch]
Covance nominates Bi Honggang as VP, GM in China

Covance, the world's second largest contract research organization (CRO), recently announced the successful nomination of Bi Honggang as Vice President and General Manager, China. Bi will lead Covance's business activities in China and represent Covance in its regulatory activities with the Chinese government. Bi Honggang received his Ph.D. in chemistry and drug metabolism from McGill University in Montreal, Canada, and has more than 15 years experience in pharmaceutical research and development at companies including SmithKline Beecham, Parke-Davis, and Pfizer. Before joining Covance, Bi worked as Chief Executive Officer of Frontage Laboratories in Malvern, Pa. Covance established its first clinical office in Beijing in 1998 and recently opened its fifth global central laboratory in Shanghai, China....   more»

AstraZeneca »24/09/2007 [Company watch]
Astra Zeneca to outsource manufacture

Anglo-Swedish drug firm AstraZeneca has today reiterated that it will outsource drug manufacturing 'where there is a sound business case.' The company issued a statement after the publication today of an interview with David Smith, AstraZeneca's executive vice-president of operations, in The Times. The newspaper reported that the company would cease and fully outsource all drug manufacturing operations within the next ten years. AstraZeneca quickly refuted the report claiming that some of Smith's comments had been misinterpreted. But the firm confirmed that part of its global view was to look more seriously at outsourcing, and that it had particular interest in opportunities in India and China. This is likely to be seen as ominous for UK manufacturing and comes just one week after the world's largest pharmaceutical company, Pfizer, revealed its decision to close its only remaining UK manufacturing plant at Sandwich in Kent, resulting in the loss of 420 jobs over the next two years. Earlier this year, AstraZeneca announced its intention to cut 3300 manufacturing jobs worldwide. But Joan Pitt, an AstraZeneca spokeswoman, told Chemistry World that this was not a signal that the company sought to move away from UK-based manufacturing. Richard Ley, a spokesman for the Association of the British Pharmaceutical Industry, told Chemistry World that there is increasing global competition for manufacturing. He warned that in the long term drug research may follow manufacturing out of the UK. 'A great deal of drug manufacturing is high-tech, so it may make more sense for companies to relocate R&D to the same place in order to have scientists working alongside each other,' Ley said....   more»

Eli Lilly & Co »24/09/2007 [Company watch]
ELi Lilly to invest $10million in R & D in China

(What happened to the $100millions!) Eli Lilly & Co, the U.S. maker of antidepressant Prozac and erectile dysfunction drug Cialis, said its China sales were rising about 26 percent a year, on track to become the company's tenth biggest global market by 2010. "We're growing 10 percent faster than the market," Jorg Ostertag, president of Lilly China said over the weekend, adding that China's drug industry grew 16 percent in 2006. China is expected to become the world's No. 7 pharmaceutical market in 2012, and the second-biggest by 2020, Ostertag said at a conference at the China Europe International Business School. China now ranks as the company's 14th biggest market. Lilly has introduced five new drugs in China this year and expects to sell 15 more in the next five years, Osgtertag said. Lilly competes with Tamiflu maker Roche and Viagra producer Pfizer Inc to sell drugs in the world's most populous country. Lilly, which two years ago partnered with China's Hisun Group on drug development, has plans to start more such alliances with Chinese firms, he said. As early as Tuesday, Lilly will sign an agreement with a unit of Hutchison Whampoa on drug development. Hutchison, a conglomerate controlled by Hong Kong tycoon Li Ka-shing, owns businesses ranging from ports to telecoms and pharmaceuticals. In June, Lilly's Asia venture capital fund invested $10 million in Chinese startup BioVeda, and said it planned to invest $10 million on research and development in the country in the next five years....   more»

Wuxi Pharma Tech »20/09/2007 [Company watch]
Wuxi (Gossip!)

WuXi PharmaTech (Cayman) Inc., and its consolidated subsidiaries, WuXi PharmaTech (BVI) Inc., or WXPT BVI, WuXi PharmaTech Co., Ltd., or WXPT, Shanghai PharmaTech Co., Ltd., or SHPT, Shanghai SynTheAll Pharmaceutical Co., Ltd., or STA, Shanghai PharmaTech Chemical Technology Co., Ltd., or SHCT, Tianjin PharmaTech Co., Ltd., or TJPT, and Suzhou PharmaTech Co., Ltd., or SZPT; They are engaged in a substantial capacity expansion program. Major projects include the expansion of Jinshan facility to quadruple the manufacturing capacity of the plant, which is currently expected to commence operations in late 2008, and the construction of a preclinical drug safety evaluation center with a broad range of toxicology services in Suzhou, which they are planning to inaugurate in 2009. These facilities may not be constructed on the anticipated timetable or within budget. The total investment of Suzhou Pharmatech (a subsidiary of Wuxi Pharmatech) is 60,000,000 US Dollars, it will run as the research center of drug safety evaluation, preclinical and clinical trials, besides these, this center provides the drug research service, medical material and R&D of bio-products. can not find any information about the building ,but I think it almost finished, because I find some job information of Wuxi Pharmatech(Suzhou).It starts to put on Ad on Web .They want to hire the Senior veterinary who will charge the routine lab work of the Primates, the animal feeder who will charge the large animal—dog and monkey to feed them and do the clean work. It is said that the Suzhou Pharmatech will become the largest Glp new drug safety evaluation center around Asia(just gossip, no official report) .In addition, I attached the new GLP center list. Hope that this information will be useful. The following is the details of the new VP of Operation of Wuxi Pharmatech ,this person worked for Bridge before....   more»

APEX International Clinical Research Co., »15/10/2007 [Company watch]
CRO Parexel expands and acquires Apex in China

Parexel International (PRXL), the CRO powerhouse, increased its presence in the China CRO market by acquiring Apex International Clinical Research Co., Ltd of Taiwan. Parexel paid $50.9 million for 93.9% of the outstanding shares. The Massachusetts company has owned a minority stake in Apex for the past four years. Apex has established offices throughout the Asia-Pacific region, including mainland China and Hong Kong. Parexel is a worldwide CRO, but it now has upped its in-house facilities in Taiwan, China and the Asia-Pacific region. In a press release, Josef von Rickenbach, Chairman and Chief Executive Officer of Parexel, said clients were demanding services in the Asia-Pacific region because of the markets there, plus the sophisticated healthcare systems and highly trained professionals in the region. He did not mention the cost savings. In a recent interview published in BioSpectrum, Albert Liou, Chairman and CEO of Apex International, said that each country has its strengths and weaknesses as a site for clinical trials, but China has the best outlook overall. Within three to five years, it will be one of the top five markets in the world, he said, so companies will develop products in China to meet the needs of its vast population. In its fiscal 2007, ended June 30, Parexel reported revenues of $742 million, up 21%, and net income of $37.3 million, an increase of 53%. Its CRO revenues were $549 million. Although Apex will be part of Parexel for only three weeks of its first quarter, Parexel said the new division would add $1 million in revenue in that quarter and up to $17 million for the 2008 fiscal year....   more»

Beijing Med-Pharm »05/10/2007 [Company watch]
Beijing Med-Pharm Corporation Expands Its Senior Management Team in China

Beijing Med-Pharm Corporation (NASDAQ: BJGP) today announced that it has named pharmaceutical executive Yanping Zhao to the new post of Corporate Vice President. Serving as the chief representative for Beijing Med-Pharm in China, Mme. Zhao will work with David Gao, CEO of Beijing Med-Pharm, to oversee and coordinate all the Company's Chinese subsidiaries. She will also have responsibility for corporate strategic business development, including mergers and acquisitions, and corporate functions in China. "We are very pleased to have an executive of Mme. Zhao's caliber join our management team," said Mr. Gao. "With an outstanding track record in operations and business development, she is very well respected in the pharmaceutical industry in China." "Beijing Med-Pharm has a first-mover advantage in controlling important distribution channels and executing a unique business model that delivers both demand creation and fulfillment," said Mme. Zhao. "This is a new way of structuring a pharmaceutical enterprise in China and I am eager to apply my expertise to continuing its growth in this dynamic market." Mme. Zhao joins Beijing Med-Pharm from China Biopharmaceutical Limited, a Hong Kong Exchange-listed company, where she served as Vice President, Executive Director and Chief Representative of the Beijing Office. While at China Biopharmaceutical in 2005, Mme. Zhao was instrumental in establishing, developing and selling 55% of Shandong China Tai Freda Pharmaceutical to Bausch & Lomb for $200 million, which at the time was the largest pharmaceutical merger and acquisition ever in China. She has also held senior management posts at Hainan Tiger Lily Pharmaceutical Co., Ltd., including General Manager and head of Research and Development, Shandong Chia Tai Freda Pharmaceutical Ltd., Xian Chia Tai Pharmaceutical Ltd., Ankang Chia Tai Pharmaceutical Ltd., and Nei Menggu Yuanbaoshan Pharmaceutical Ltd. She began her industry career at the China Nei Mengu Autonomous Region Medicine and Health Products Import & Export Corporation, ultimately serving as Director. Mme. Zhao holds a degree from Shenyang Pharmaceutical University and an MBA from Dalian University of Technology....   more»

Charles River »22/10/2007 [Company watch]
Charles River expansion in China

1. Joint venture with Bioexplorer (Bioexplorer was set up in January 2005, a preclinical contract research company, its main customer includes Lily, Roche and Pfizer) was signed on March 2007. 2. Transaction completed on June 15 2007. 2. The joint venture company will be known as Charles River Laboratories Preclinical Services – China, which Charles River will be the majority owner. 3. Company plan- Phase One l 6000 square meter Pre-existing shell; l 38 study rooms; l 17 non-rodent rooms; l 21 rodent rooms; l Clean/dirty corridor; l Construction started in Oct.2007, and will be completed in May 2008; l Non-clinical pilot studies will begin in May 2008; l Open for business in July 2008; l Fully GLP validation will be finished in Aug.2008; l Receive AAALAC accredited in Feb.2009; l globally. It will build 120 studies rooms in 3-5 years. l Phase Two will meet the European animal welfare standard. l The final goal of service will be EMEA and US FDA GLP compliance. 5. Staff l CRL China have 45 staff now. They want to have 120 staff initially and then 225 in full. Senior staff will be sent to Montreal to train for 9-12 months. Currently there are 5 staffs in training in Montreal. l The Montreal experts will be sent to Shanghai to support this newly established lab. l Kewen also wants to collaborate with some big pharms to provide some training courses to the students (toxicology, phathology and veterinary) in Chinese University of Agriculture. 6. The existing IT system ensures earlier integration and data consistency. 7. Animal Resources: l Non Human Primates from Chinese supplier; 4. Company plan- Phase Two l This laboratory will become the second largest site of Charles River Dogs from Marshall-a joint venture company in Beijing; l SPF rodent import from Charles River Lab Japan; l Large rodent will come from Charles River Lab China Rodent facility which will be nearby and supply service throughout China. 8. Caging Have three Chinese suppliers making prototype at the moment. The one they choose will supply Charles River globally....   more»

AstraZeneca »22/10/2007 [Company watch]
AstraZeneca outsources manufacture to China in a bid to reduce costs

AstraZeneca has begun to outsource production of some of its bestselling medicines to low-cost manufacturers in China, Times Online reported. As part of a restructuring drive designed to cut $900 million (£440 million) of the drugs group’s costs by 2010, the drugs giant is to begin purchasing Lactam, a key chemical ingredient used to make Seroquel, its blockbuster schizophrenia drug, from contract manufacturers in China....   more»

»17/10/2007 [Company watch]
Ranbaxy make China major sourcing hub

Pharmaceuticals major Ranbaxy Laboratories plans to leverage the cost advantage of Chinese raw materials by making China its major active pharmaceutical ingredient (API) sourcing hub. The company, which already has a Chinese presence through a joint venture named Ranbaxy Guangzhou China (RGCL), will explore new partnership options to facilitate raw material outsourcing. RGCL would continue to focus on manufacturing medicines for exclusive supplies to the Chinese market, Malvinder Mohan Singh, CMD, Ranbaxy said. Speaking to reporters on the sidelines of a CII conference on life sciences today, Singh said that Ranbaxy saw China's low-cost raw material manufacturing ability not as a threat, but as an opportunity for reducing its manufacturing expenses. The company's interest in API manufacturing will continue to be strong. However, we will try to maximise our profits by importing huge quantities of APIs from China, he explained. The company is also expecting to expand its bio-similar drugs (low cost biotechnology medicines) business in a big way. Bio-similars have a great future. Lot of capabilities and knowledge have to be unlocked in this segment, he added. According to Singh, Ranbaxy plans to create a lot of value by leveraging on the strength of its newly acquired biotech company, Zenotech Laboratories. Zenotech has two biotechnology-based cancer offerings in India and eight more are being developed. Its medicines are expected to be cleared for shipping to Europe by 2011. Singh also hinted that Ranbaxy would continue to explore business opportunities in areas where there are high entry barriers. We are evaluating speciality areas where there is less competition. Ranbaxy may enter such areas, oncology for instance, in future, he said. <Previous Next>...   more»

»16/10/2007 [Company watch]
AMDL expands drug distribution in China

AMDL, Inc. , headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin, China, through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI), is an international biopharma company that engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products. AMDL announced today that JPI has signed an agreement with Heze Mudan Medicals Co. Ltd. to distribute Domperidone tablets in the Province of Shandong and the surrounding areas, one of the most affluent regions in China. Domperidone is an important medicine for treating nausea and vomiting. JPI's generic version of this product is significantly lower priced than competitors. The contract is subject to minimum sales which will be reviewed annually and is expected to add at least $2.3 million in annual revenues. Frank Zheng, managing director of JPI, said this transaction puts the Company on the path to building sales in China by as much as $24 million over the next 12 months. Gary Dreher, CEO of AMDL, said this and other recently signed contracts will assist in the effort to meet the goal of building annual sales to $100 million over the next four to five years. About JPI: Jade Pharmaceutical has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiary, Jade currently manufactures large volume injectable fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards. About AMDL: More information about AMDL and its products can be obtained at . Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur....   more»

Shanghai ChemPartner Co.,Ltd. »30/10/2007 [Company watch]
ShangPharma Receives Strategic Investment from TPG

ShangPharma Corporation ("ShangPharma" or the "Group"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that leading global private investment firm TPG, through its TPG Growth Fund and TPG Biotech Fund (collectively known as "TPG"), has invested over US$30 million into the Group....   more»

MDS Pharma Services »26/10/2007 [Company watch]
MDS Pharma - Grand Opening of Central Lab in Beijing

New Beijing Global Central Lab The new 24,000 square foot global central lab in Beijing offers even more diverse testing techniques and platforms and increased testing capacity. With 10 years of experience in China this all new facility offers unmatched central lab services, including in-house project and data management support as well as kit production for better control and quick study set up, in-house testing for consistency and seamless data, and the all-new Apollo Study Management System which ensures transparent tracking of samples and data, so your study will run smoothly right up to final data lock....   more»

Shanghai ChemPartner Co.,Ltd. »03/11/2007 [Company watch]
China drug R&D outsourcing firm mulls IPO

Shangpharma Corp, the second-largest pharmaceutical and biotechnology research outsourcing firm in China, is considering an initial public offering at a time when investors are lapping up Chinese stocks....   more»

3SBIO (Shenyang Sunshine) »03/11/2007 [Company watch]
3SBio takes lion share in China's EPO market

Recombinant human erythropoietin (EPO) injection product Epiao of Shenyang Sunshine Pharmaceutical Co., Ltd. (3Sbio, SSRX.NASDAQ) has seen brisk sales and now takes a market share of 37 percent in China....   more»

Roche »30/10/2007 [Company watch]
Roche Drug center in Shanghai to tackle cancer and diabetes

Shanghai's first international drug development center was launched Monday to help Chinese researchers and patients become involved in international trials for new medicines. The Pharma Development Center in China, which is backed by the international pharmaceutical company Roche, is a high tech drug development center designed to effectively carry out all the stages of drug development from discovery to clinical development, trials and official paper work....   more»

»30/10/2007 [Company watch]
Bio-Bridge Science, Inc. Executed Letter of Intent to Acquire 51% of Lanzhou Roya Biotechnology Co.,

IS THIS COMPANY LINKED TO BRIDGE or "VITAL BRIDGE" Bio-Bridge Science, Inc. (OTCBB:BGES), a biotechnology company engaged in the commercial development of vaccines for the prevention and treatment of human infectious diseases, announced today that it has executed a non-binding letter of intent to acquire 51% of Lanzhou Roya Biotechnology Co. Ltd., based in the People's Republic of China. Lanzhou Roya is a bovine serum manufacturer in China. The serum market size in China is estimated to be RMB 500 million per annum. Bovine serum is used in production of many vaccines as well as for laboratory scientific research....   more»

Eli Lilly & Co »08/11/2007 [Company watch]
Eli Lilly plans more drug development in China

U.S. pharmaceutical firm Eli Lilly & Co (LL.N:, maker of antidepressant Prozac and erectile dysfunction drug Cialis, said on Thursday it plans to develop more drugs in China because of lower costs and an ample pool of talent. "We need to find a way to establish leadership in China, not only by selling drugs," Darren Carroll, senior managing director of Lilly Asian Ventures, said in an interview. The cost for a researcher in China is as little as 20 percent of the cost in the United States, where one out of five of Lilly's researchers is Chinese, Carroll said. "We believe we should find ways to come to the innovators, rather than having them all come to the U.S."...   more»

3SBIO (Shenyang Sunshine) »15/11/2007 [Company watch]
3SBio Inc. Q3 net far outgrows revenue

Chinese biotech company 3SBio Inc. ( SSRX.NASDAQ) posted 57.3 percent net revenue rise in the 3rd quarter from the same period of 2006 to 7.5 million U.S. dollars, according to its latest financial report issued on Tuesday....   more»

Shanghai ChemPartner Co.,Ltd. »15/11/2007 [Company watch]
LEAD Therapeutics Announces Strategic Research Collaboration with ShangPharma

LEAD Therapeutics, Inc., a chemistry-driven drug discovery company based in the San Francisco Bay Area, today announced it has entered into a strategic research collaboration with Shanghai ChemPartner in China, the wholly owned subsidiary of ShangPharma. In conjunction with this collaboration, China Gateway Life Science (Holding) Ltd., the strategic investment arm of ShangPharma, has made an equity investment in LEAD Therapeutics. Previously announced investors include Pappas Ventures, ProQuest Investments, and Mustang Ventures....   more»

»14/11/2007 [Company watch]
Renhuang Pharmaceuticals Rated ‘Outperform’ Target Price $7.00 by Beacon Equity Research

Renhuang Pharmaceuticals (OTCBB:RHGP) has been rated Outperform with a price target of $7.00 by Beacon Equity Research Analyst, Lisa Springer, CFA....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.